Kempenhaeghe
- Address
- lock Available on a paid plan
Epilepsy Therapeutics Research
The Sleep Medicine Centre at Kempenhaeghe is advancing treatment options for epilepsy. Studies aim to lower seizure counts and evaluate long‑term safety of emerging medicines.
- Refractory epilepsy
- Primary generalized tonic‑clonic seizures
- Focal onset seizures
- Dravet syndrome and Lennox‑Gastaut syndrome
- Idiopathic generalized epilepsy
- Adjunctive cannabidiol therapy
- Novel oral agents such as XEN1101 and BHV‑7000
A total of nine trials involving five investigators are currently recruiting or ongoing, offering patients access to cutting‑edge interventions while generating data that could reshape seizure management.
Sleep and Neurological Conditions
Research at the centre also addresses sleep disturbances that accompany neurological disease. The goal is to improve sleep quality and overall wellbeing through targeted therapies.
- Insomnia management in adults
- Sleep quality in multiple sclerosis
- Impact of cannabidiol on sleep patterns
- Non‑pharmacologic sleep interventions
- Sleep monitoring in patients with epilepsy
By integrating sleep assessments into epilepsy trials, the site provides a holistic view of patient health, supporting better outcomes for both seizure control and restorative rest.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1Xenon Pharmaceuticals Inc.3active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Xenon Pharmaceuticals Inc.3trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 271 other sites in The Netherlands
Therapeutic Area Benchmark — The Netherlands
Select a therapeutic area to compare against other sites in The Netherlands.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: The Netherlands
Market Share
Country: The Netherlands
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Kempenhaeghe
lock Showing 1 of 13 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of XEN1101 in Subjects Diagnosed With Epilepsy (X-TOLE4) | Xenon Pharmaceuticals Inc. | Phase III | Recruiting | Feb 2024 | — |
IMP list
lock Showing 1 of 8 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Azetukalner | 3 | Unknown | 2023-09-27 | 2024-02-14 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.